| Literature DB >> 26434739 |
Mohammed Awais Hameed1, Mark Pucci2, Una Martin2,3, Richard Watkin1, Sagar Doshi2, Jonathan Freedman1, Peter Riley2, Jonathan Townend2, Paul Crowe1, Graham Lipkin2, Indranil Dasgupta1.
Abstract
Renal denervation (RDN) has emerged as a potential device-based treatment for resistant hypertension. The authors present their experience of the use of catheter-based RDN as part of routine clinical care in two specialist hypertension clinics. Thirty-four patients with uncontrolled hypertension underwent RDN. All patients had ambulatory blood pressure (BP) monitoring and directly observed medication administration prior to the procedure to exclude white-coat hypertension and nonadherence, respectively. Overall, there was a significant change in clinic systolic BP of -15.1 mm Hg (95% confidence interval, -23.4 to -6.8; P=.001) and clinic diastolic BP of -6.2 mm Hg (95% confidence interval, -11.5 to -0.9; P=.02) 6 months postprocedure, and a nonsignificant change in daytime ambulatory BP of -5.4/-2.9 mm Hg. Eighteen patients (51.4%) showed a significant reduction in their clinic systolic BP (≥10 mm Hg) and 16 (47%) had a significant reduction in their daytime ambulatory systolic BP (≥5 mm Hg) at 6 months.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26434739 PMCID: PMC8031673 DOI: 10.1111/jch.12713
Source DB: PubMed Journal: J Clin Hypertens (Greenwich) ISSN: 1524-6175 Impact factor: 3.738